Asset Details
Do you wish to reserve the book?
Kinase activities in pancreatic ductal adenocarcinoma with prognostic and therapeutic avenues
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Kinase activities in pancreatic ductal adenocarcinoma with prognostic and therapeutic avenues
Do you wish to request the book?
Kinase activities in pancreatic ductal adenocarcinoma with prognostic and therapeutic avenues
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Kinase activities in pancreatic ductal adenocarcinoma with prognostic and therapeutic avenues
2024
Overview
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a limited number of known driver mutations but considerable cancer cell heterogeneity. Phosphoproteomics provides a direct read‐out of aberrant signaling and the resultant clinically relevant phenotype. Mass spectrometry (MS)‐based proteomics and phosphoproteomics were applied to 42 PDAC tumors. Data encompassed over 19 936 phosphoserine or phosphothreonine (pS/T; in 5412 phosphoproteins) and 1208 phosphotyrosine (pY; in 501 phosphoproteins) sites and a total of 3756 proteins. Proteome data identified three distinct subtypes with tumor intrinsic and stromal features. Subsequently, three phospho‐subtypes were apparent: two tumor intrinsic (Phos1/2) and one stromal (Phos3), resembling known PDAC molecular subtypes. Kinase activity was analyzed by the Integrative iNferred Kinase Activity (INKA) scoring. Phospho‐subtypes displayed differential phosphorylation signals and kinase activity, such as FGR and GSK3 activation in Phos1, SRC kinase family and EPHA2 in Phos2, and EGFR, INSR, MET, ABL1, HIPK1, JAK, and PRKCD in Phos3. Kinase activity analysis of an external PDAC cohort supported our findings and underscored the importance of PI3K/AKT and ERK pathways, among others. Interestingly, unfavorable patient prognosis correlated with higher RTK, PAK2, STK10, and CDK7 activity and high proliferation, whereas long survival was associated with MYLK and PTK6 activity, which was previously unknown. Subtype‐associated activity profiles can guide therapeutic combination approaches in tumor and stroma‐enriched tissues, and emphasize the critical role of parallel signaling pathways. In addition, kinase activity profiling identifies potential disease markers with prognostic significance. Despite the treatment advancements in pancreatic ductal adenocarcinoma, 5‐year survival rates are still below 10%. Analyzing the phosphoproteome of 42 tumors, three subtypes with intrinsic and stromal features were revealed, each displaying kinase activity patterns with potential treatment options. Kinase activities associated with specific mutations, and correlated with clinical prognosis. This study provides insights for tailored and combination strategies.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
1-Phosphatidylinositol 3-kinase
/ Aged
/ Carcinoma, Pancreatic Ductal - enzymology
/ Carcinoma, Pancreatic Ductal - metabolism
/ Carcinoma, Pancreatic Ductal - pathology
/ Female
/ Humans
/ Kinases
/ Male
/ Pancreas
/ pancreatic ductal adenocarcinoma
/ Pancreatic Neoplasms - enzymology
/ Pancreatic Neoplasms - genetics
/ Pancreatic Neoplasms - metabolism
/ Pancreatic Neoplasms - pathology
/ Peptides
/ Proteins
/ Stroma
/ Tumors
